Cell proliferation, apoptosis, oncogene, and tumor suppressor gene status in adenosis with comparison to benign prostatic hyperplasia, prostatic intraepithelial neoplasia, and cancer

Human Pathology

Volumn 30, Issue 9, 1999, Pages 1077-1086

  Häussler, Oliver ^b   Epstein, Jonathan I ^b   Amin, Mahul B ^b   Heitz, Philipp U ^b   Hailemariam, Seife ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b NONE

Author keywords

Adenosis; Apoptosis; Atypical adenomatous hyperplasia; bcl 2; c erbB 3 her 3; c erbB 2 her 2; p53; Proliferation; Prostate carcinoma; Prostatic intraepithelial neoplasia

Indexed keywords

PROTEIN BCL 2; PROTEIN P53;

ADENOMA; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; TUMOR SUPPRESSOR GENE;

EID: 0032888333     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(99)90226-5     Document Type: Article

References (68)

1. Bostwick DG, Amin MB, Dundore P, et al: Architectural patterns of high-grade prostatic intraepithelial neoplasia. HUM PATHOL 24:298-310, 1993
2. Emmert-Buck MR, Vocke CD, Pozzatti RO, et al: Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res 55:2959-2962, 1995
3. Epstein JI, Grignon DJ, Humphrey PA, et al: Intraobserver reproducibility in the diagnosis of prostatic intraepithelial neoplasia. Am J Surg Pathol 19:873-886, 1995
4. Epstein JI: Pathology of prostatic intraepithelial neoplasia and adenocarcinoma of the prostate: Prognostic influences of stage, tumor volume, grade and margins of resection. Semin Oncol 21:527-541, 1994
5. Helpap BGT, Bostwick DG, Montironi R: The significance of atypical adenomatous hyperplasia and prostatic intraepithelial neoplasia for the development of prostate carcinoma. Virchows Arch 426:425-434, 1995
6. Qian J, Bostwick DG, Takahashi S, et al: Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res 55:5408-5414, 1995
7. Bostwick DG, Qian J: Atypical adenomatous hyperplasia of the prostate: Relationship with carcinoma in 217 whole-mount radical prostatectomies. Am J Surg Pathol 19:506-518, 1995
8. Bostwick DG, Srigley J, Grignon D, et al: Atypical adenomatous hyperplasia of the prostate: Morphologic criteria for its distinction from well-differentiated carcinoma. HUM PATHOL 24:819-832, 1993
9. Epstein JI: Adenosis (atypical adenomatous hyperplasia): Histopathology and relationship to carcinoma. Pathol Res Pract 191:888-898, 1995
10. Gaudin PB, Epstein JI: Adenosis of the prostate: Histologic features in transurethral resection specimens. Am J Surg Pathol 18:863-870, 1994
11. Gaudin PB, Epstein JI: Adenosis of the prostate: Histologic features in needle biopsy specimens. Am J Surg Pathol 19:737-747, 1995
12. Qian J, Jenkins RB, Bostwick DG: Chromosomal anomalies in atypical adenomatous hyperplasia and carcinoma of the prostate using fluorescence in situ hybridization. Urology 46:837-842, 1995
13. Gavrieli Y, Sherman Y, Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119:493-501, 1992
14. Van den Berg FM, Baas IO, Polak MM, et al: Detection of p53 overexpression in routinely paraffin-embedded tissue of human carcinomas using a novel target unmasking fluid. Am J Pathol 142:381-385, 1993
15. Jones EC, Young RH: The differential diagnosis of prostate carcinoma: Its distinction from premalignant and pseudocarcinomatous lesions of the prostate. Am J Clin Pathol 101:48-64, 1994
16. Troncoso P, Ayala AG: Atypical small glandular proliferations of the transition zone in cystoprostatectomy specimens. Mod Pathol 7:85A, 1994
17. Renedo D, Poy E, Wojno KJ: Clinical significance and distinction of adenosis from low-grade adenocarcinoma of the prostate on TURP. Mod Pathol 8:82A, 1995
18. Gerdes J, Lemke H, Baisch H, et al: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133:1710, 1984
19. Bonkhoff H, Stein U, Remberger K: The proliferative function of the basal cells in the normal and hyperplastic human prostate. Prostate 24:114-118, 1994
20. Helpap B, Riede C: Nucleolar and AgNOR-analysis of the prostatic intraepithelial neoplasia (PIN), atypical adenomatous hyperplasia (AAH) and prostatic cancer. Pathol Res Pract 191:381-390, 1995
21. Helpap B: Cell kinetic studies on prostatic intraepithelial neoplasia (PIN) and atypical adenomatous hyperplasia (AAH) of the prostate. Pathol Res Pract 191:904-907, 1995
22. Tamboli P, Amin MB, Schultz DS, et al: Comparative analysis of the nuclear proliferation index (Ki-67) in benign prostate, prostatic intraepithelial neoplasia, and prostate carcinoma. Mod Pathol 9:1015-1019, 1996
23. Colombel M, Olsson A, Ng PY, et al: Hormone-regulated apoptosis results from reentry of differentiated prostate cells onto a defective cell cycle. Cancer Res 52:4313-4319, 1992
24. Denmeade SR, Lin XS, Isaacs JT: Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 28:251-265, 1996
25. Harriss DR, Savill J: Apoptosis and the prostate. Br J Urol 75:27-33, 1995 (suppl 1)
26. Montironi R, Magi-Galluzzi C, Fabris G: Apoptotic bodies in prostatic intraepithelial neoplasia and prostatic adenocarcinoma following total androgen ablation. Pathol Res Pract 191:873-880, 1995
27. Schwartman RA, Cidlowski JA: Apoptosis: The biochemistry and molecular biology of programmed cell death. Endocr Rev 14:133-151, 1993
28. Ansari B, Coates PJ, Greenstein BD, et al: In situ end-labeling detects DNA strand breaks in apoptosis and other physiological and pathological states. J Pathol 170:1-8, 1993
29. Coates PJ, Save V, Ansari B, et al: Demonstration of DNA damage/repair in individual cells using in situ end labeling: Association of p53 with sites of DNA damage. J Pathol 176:19-26, 1995
30. Sträter J, Günthert AR, Brüderlein S, et al: Microwave irradiation of paraffin-embedded tissue sensitizes the TUNNEL method for in situ detection of apoptotic cells. Histochem Cell Biol 103:157-160, 1995
31. Berges RR, Vukanovic J, Epstein JI, et al: Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1:473-480, 1995
32. Bakshi A, Jensen JP, Goldman P, et al: Cloning the chromosomal breakpoint of t(14;18) human lymphomas: Clustering around JH on chromosome 14 and near a transcription unit 18. Cell 41:889-906, 1985
33. Hockenbery DM, Nunez G, Milliam C, et al: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334-336, 1990
34. Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol 124:1-6, 1994
35. Herrmann JL, Menter DG, Beham A, et al: Regulation of Iipid signaling pathways for cell survival and apoptosis by bcl-2 in prostate carcinoma cells. Exp Cell Res 234:442-451, 1997
36. Hockenbery DM, Zutter M, Hickey W, et al: Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Nad Acad Sci U S A 88:6961-6965, 1991
37. Bonkhoff H, Remberger K: Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: A stem cell model. Prostate 28:98-106, 1996
38. Colombel M, Symmans F, Gil S, et al: Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 143:390-400, 1993
39. Bauer JJ, Sesterhenn IA, Mostofi FK, et al: Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol 156:1511-1516, 1996
40. Bubendorf L, Sauter G, Moch H, et al: Prognostic significance of bcl-2 in clinically localized prostate cancer. Am J Pathol 148:1557-1565, 1996
41. McDonnell TJ, Troncoso P, Brisbay SM, et al: Expression of the protoncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52:6940-6944, 1992
42. Moul JW, Bettencourt MC, Sesterhenn IA, et al: Protein expression of p53, bcl-2, and Ki-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery 120:159-167, 1996
43. Theodorescu D, Broder SR, Boyd JC, et al: p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J Urol 158:131-137, 1997
44. Lyne JC, Melhem MF, Finley GG, et al: Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro. Cancer J Sci Am 3:21-30, 1997
45. Peles E, Bacus SS, Koski RA, et al: Isolation of the Neu/ HER-2 stimulatory ligand: A 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell 69:205-216, 1992
46. Prigent SA, Lemoine NR: The type I (EGFR-related) family of growth factor receptors and their ligands. Progress in Growth Factor Research 4:1-24, 1992
47. Fournier G, Latil A, Amet Y, et al: Gene amplification in advanced-stage human prostate cancer. Urol Res 22:343-347, 1995
48. Giri DK, Pal R, Wadhwa SN, et al: Immunohistochemical localization of transforming growth factor-, epidermal growth factor receptor and c-erbB-2 protein in hyperplastic human prostates. Carcinogenesis 16:729-733, 1995
49. neu) in prostate tumors: an immunohistochemical study. Prostate 23:329-336, 1993
50. Kuhn EJ, Kurnot RA, Sesterhenn IA, et al: Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. J Urol 150:1427-1433, 1993
51. erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J Natl Cancer Inst 86:1140-1145, 1994
52. Prigent SA, Lemoine NR, Hughes CM, et al: Expression of the c-erbB-3 protein in normal human adult and fetal tissues. Oncogene 7:1273-1278, 1992
53. Ross JS, Nazeer T, Church K, et al: Contribution of HER-2/ neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis. Cancer 72:3020-3028, 1993
54. Sadasivan R, Morgan R, Jennings S, et al: Overexpression of HER-2/NEU may be an indicator of poor prognosis in prostate cancer. J Urol 150:126-131, 1993
55. Visakorpi T, Kallioniemi OP, Koivula T, et al: Expression of epidermal growth factor receptor and ERBB2 (HER-2/Neu) oncoprotein in prostatic carcinomas. Mod Pathol 5:643-648, 1992
56. Ware JL, Maygarden SJ, Koonitz WW, et al: Immunohistochemical detection of c-erbB-2 protein in human benign and neoplastic prostate. HUM PATHOL 22:254-258, 1991
57. Zhau HE, Wan DS, Zhou J, et al: Expression of c-erbB-2/neu proto-oncogene in human prostatic cancer tissues and cell lines. Mol Carcinog 5:320-327, 1992
58. Fox SB, Persad RA, Coleman N, et al: Prognostic value of c-erbB-2 and epidermal growth factor receptor in stage A1 (T1a) prostatic adenocarcinoma. Br J Urol 74:214-220, 1994
59. Veltri RW, Partin AW, Epstein JI, et al: Quantitative nuclear morphometry, markovian texture descriptors, and DNA content captured on a CAS-200 image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression. J Cell Biol 19:249-258, 1994 (suppl)
60. Latil A, Baron JC, Cussenot O, et al: Oncogene amplifications in early-stage human prostate carcinomas. Int J Cancer 59:637-638, 1994
61. Hall PA, Lane DP: p53 in tumor pathology: Can we trust immunohistochemistry? Revisited! J Pathol 172:1-4, 1994
62. Harris CC, Hollstein M: Clinical implication of the p53 tumor suppressor gene. N EnglJ Med 329:1318-1327, 1993
63. Lane DP, Benchimol S: p53 oncogene or anti-oncogene? Genes Dev 4:1-8, 1990
64. Levine AJ, Momand J, Finlay CA: The p53 tumor suppressor gene. Nature 351:453-456, 1991
65. McDonnell TJ, Navone MN, Troncoso P, et al: Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J Urol 157:569-574, 1997
66. Myers RB, Oelschlager D, Srivastava S, et al: Accumulation of the p53 protein occurs more frequently in metastatic than in localized prostatic adenocarcinomas. Prostate 25:243-248, 1994
67. Navone NM, Troncoso P, Pisters LL, et al: p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 85:1657, 1993
68. Van Veldhuizen PJ, Sadasivan R, Cherian R, et al: p53 expression in incidental prostate cancer. Am J Med Sci 305:275-279, 1993